-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From yesterday to today, domestic new crown vaccines have been successively reported good news and have been approved for emergency use
.
As of the time of writing, the number of new crown vaccines on the market in China has reached 12, and it is still expected to continue to increase
.
Yesterday (12.
4) afternoon, Shenzhou Cell announced that it recombinant new coronavirus 2 valent (Alpha/Beta variant) S
Trimeric protein vaccine (project code: SCTV01C) has been included in emergency use
by relevant national departments.
This morning (12.
5), Clover announced that the new crown vaccine SCB-2019 (CpG
1018/aluminum) has been evaluated by the relevant authorities in China and is included in emergency use
in China.
At noon, Sichuan University announced the recombinant novel coronavirus protein vaccine (Sf9) developed by West China Hospital
Cryptosin) was included in emergency use, becoming the first recombinant protein novel coronavirus protein vaccine
approved for emergency use.
In the afternoon, Wantai Biotech announced that its nasal spray virus vector new crown vaccine was approved for emergency use
.
This is after CanSino, No.
2
Approved non-injectable vaccines
.
With the development of the epidemic prevention and control situation, it is expected that more vaccines and therapeutic drugs will gradually bear fruit, contributing more to
the domestic epidemic prevention and control.
Which other companies and products are about to cross the line in the future? Insight
A simple overview
of the data is available.
12 new crown vaccines were approved, 14 clinical III The development of new vaccines focuses on Omicron
12 new crown vaccines were approved, 14 clinical III The development of new vaccines focuses on OmicronAccording to the Insight database, there are currently 12 in China
Approved COVID vaccines
.
These approved vaccines cover a variety of technical routes, different delivery methods and different new coronavirus strains, including inactivated vaccines, adenovirus vaccines, and recombinant protein vaccines; injectable and inhaled vaccines; The original strain of the new crown and
Alpha、Beta.
.
.
.
.
.
Chinese mainland approved coronavirus vaccine
Screenshot from: Insight database (http://db.
dxy.
cn/v5/home/)
At the same time, three vaccines have been approved overseas, but not
domestically.
These include Sinopharm's second-generation new crown vaccine, Watson/Abogen and Fosun Pharma/BioNTech's mRNA
Vaccines
.
New crown vaccines approved overseas but not yet approved domestically
Screenshot from: Insight database
The follow-up development of mRNA vaccines is also a hot topic in the industry
.
From the perspective of clinical phase III vaccines, 4 mRNAs are also included in the vaccine projects laid out by 14 Chinese companies
Vaccines, from Microbios, Providence, CanSino Biologics and Emmy vaccines
.
The focus on the Omicron strain can also be clearly seen from the current vaccines under development, such as Zhifei Biotechnology this year
Phase III clinical trials were just launched in November with the Omicron-Delta strain recombinant new coronavirus protein vaccine
.
The first 3 to be listed in China
Beijing Biotech, Wuhan Biotech and Sinovac, the research and development companies of inactivated vaccines, also opened phase III clinical trials
of Omicron inactivated vaccines almost simultaneously in May this year.
Clinical III of domestic enterprise layout
Phase phase vaccines
Screenshot from: Insight database data
Insight shows that there are currently 37 new crown mRNA vaccines that domestic companies have participated in, of which 21 have entered the clinic
.
CSPC's mRNA vaccine has attracted much attention,6
Two of the clinical studies have been submitted to CDE, and the facility has been established to be GMP-compliant for subsequent emergency use
The production workshop and obtained the drug production license granted by the Hebei Provincial Food and Drug Administration ensure the supply of vaccines, and key raw materials and excipients can be independently produced by CSPC, which realizes independent control in the supply chain and greatly reduces production costs
.
The new crown treatment drugs Azvudine and Paxlovid have been approved 10 III
According to the Insight database, small molecule drugs for COVID-19 are currently being developed at 3CLPRO, RDRP
The targets are densely clustered, in addition to the development
of new crown indications for other marketed old drugs.
3CL protease is a key protease necessary for the replication of the novel coronavirus, and this target is typically represented by Pfizer's
PF-07321332, which together with the low-dose antiretroviral drug ritonavir (Ritonavir) constitutes an oral combination Paxlovid
.
RNA polymerase inhibitors rank second only to 3CL protease inhibitors, targeting RDRP (RNA-dependent RNA polymerase), to Merck's
Molnupiravir, Gilead's Remdesivir, Junshi Biologics/Wangshan Wangshui
Renmindevir (VV116) is a typical representative
.
These three drugs are currently approved for marketing, of which VV116 is approved in Uzbekistan
.
Domestic progress new crown chemical drugs
Screenshot from: Insight database
In terms of small molecule drugs, only Paxlovid and azvudine have been approved for marketing
in China.
The other two declared chemicals are imported, Merck's Molnupiravir and Shiono's
Ensitrelvir
。 Domestic declared/approved new crown oral drugs
Screenshot from: Insight database
Among the unmarketed new drugs, one of the most anticipated products may be Junshi Biologics' Renmindevir
.
Last year 12
The drug was approved for emergency use in Uzbekistan in January, and the price disclosed in the middle of the year was $185 a course of treatment; This year, phase II/III clinical trials and 3 phase III clinical trials were initiated, and Pfizer was launched head-to-head
The Paxlovid study achieved a statistically superior effect, with patients receiving VV116 compared to Paxlovid
Median to sustained clinical recovery time to treatment is shorter
.
When will the line be collided next? This result is highly anticipated
.
Renmindevir Global R&D Progress Gantt chart
Screenshot from: Insight database
Let's look at the phase III oral drugs
of the new crown that other domestic companies have participated in the research and development.
Among them, Forbutevir of Frontier Biologics, SIM0417 of Simcere Pharmaceutical, and RAY1216 of Zhongsheng Pharmaceutical all belong to 3CL
Protease inhibitors, Ascletis ASC09F is an HIV-1 protease inhibitor
.
Ascletis also deployed the RdRp inhibitors ASC10, ASC10-A and 3CL protease inhibitors
ASC11, both in early stages of development
.
Domestic participation in the research and development of phase III and II/III phase new crown oral drugs
Screenshot from: Insight database
